The Liver Meeting 2014 - AASLD (American Association for the study of Liver Diseases)

-
Boston, MA
,

Three posters relating to our Lumipulse® G HBV panel will be presented at this event:

(UPDATE - the posters are now available for download, click on each title below to open and download):

  • "HBcrAg levels in patients with chronic hepatitis B undergoing NUC therapy"
    The aim of the study was to analyze HBcrAg levels in a European cohort during NUC-therapy. Patients with chronic Hep B, both untreated and ineffectively treated, started a new NUC-treatment as antiviral therapy. These patients had a random pos/neg HBeAg status. Most important conclusions from this study are:
    - During antiviral therapy, HBcrAg showed different kinetics than HBV DNA and HBsAg
    - HBcrAg levels declined rapidly in the first 12-24 of NUC-therapy, followed by a slow decline
    - A low HBcrAg level, with undetectable HBV DNA level, may help to identify patients with a higher chance of HBeAg and HBsAg clearance
      
  • "Hepatitis B core related antigen levels are associated with response to ETV and PEG-IFN treatment in HBeAg-positive chronic Hepatitis B patiantens"
    The aim of this study was to investigate the role of serum HBcrAg levels in relation to antiviral therapy for chronic hepatitis B patients. HBeAg positive patients, treated initially with ETV (entecavir), followed by either PEG IFN add-on or continued with ETV-monotherapy, were studied for HBeAg-loss with HBV DNA < 200 IU/ml. Both in patients treated with PEG-IFN add-on as in patients treated with ETV-monotherapy, HBcrAg showed a clear decline, although more prominent in PEG-IFN add-on.
     
  • "Hepatitis B core related antigen levels differ during the natural history of chronic Hepatitis B infection"
    The aim of this study was to investigate serum HBcrAg levels through the different phases of chronic Hepatitis B infection and the correlation between other virologic markers. The different phases were identified in Immune Tolerant (IT), HBeAg(+) Active (IA+), Inactive Carrier (IC) and HBeAg(-) Active (IA-) patient groups. The different virologic markers (disease phenotypes) were identified with HBeAg status, HBV DNA levels and serum ALT levels. There was a significant correlation between HBcrAg and the disease phenotype; highest correlation in IT, lowest in IC. HBcrAg levels may have additional value in differentiating between HBV phenotypes.

If you would like us to set up a meeting with a person from our team during the event please let us know through the contact form below (requires sign up for our eServices):

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.